Midday Report: Immunovant (IMVT) Gains on June 21

Equities Staff  |

Immunovant Inc (NASDAQ: IMVT) has risen $0.19 (5.29%) and is currently sitting at $3.79, as of 11:59:03 est on June 21.

96,964 shares have been traded today.

The Company rose 5.59% over the last 5 days and shares have fallen 7.95% over the last 30 days.

Immunovant expects its next earnings on 2022-08-09.

For technical charts, analysis, and more on Immunovant visit the company profile.

About Immunovant Inc

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.

To get more information on Immunovant Inc and to follow the company's latest updates, you can visit the company's profile page here: Immunovant Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade

Market Movers

Sponsored Financial Content